BackPraxis Precision Medicines Overview

Praxis Precision Medicines Long Term Debt

Praxis Precision Medicines's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Praxis Precision Medicines Long Term Debt History

Loading

Praxis Precision Medicines vs. peers: Long Term Debt Comparison

Loading

Praxis Precision Medicines Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Praxis Precision Medicines (PRAX) FAQ

The latest long-term debt for PRAX is $0 as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Praxis Precision Medicines's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRAX's long-term debt moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Praxis Precision Medicines's operating scale or balance-sheet position.

A long-term debt figure of $0 for PRAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PRAX's long-term debt ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Praxis Precision Medicines's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.